Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Lexicon Genetics grants sublicense to Avatar BioSci for use of gene-trapping technology

Sep. 9, 1999

Theratechnologies and Atrix sign bone research collaboration

Sep. 9, 1999

Potent, selective human beta3-adrenoceptor antagonists discovered at Merck & Co.

Sep. 7, 1999

Celera Genomics and Gemini Research establish research collaboration

Sep. 7, 1999

SkyePharma acquires nanoparticle technology

Sep. 7, 1999

PDL granted new European patent covering humanized monoclonal antibodies

Sep. 7, 1999

3-Dimensional awarded two research grants from NIH

Sep. 6, 1999

Ligand and Parke-Davis establish research collaboration

Sep. 6, 1999

Licensing opportunity from NIH: drug delivery system for water-insoluble drugs

Sep. 6, 1999

Orally bioavailable, ETB receptor-selective antagonists designed by Abbott

Sep. 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...